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The Th17-mediated immune response was investigated in patients chronically infected with hepatitis C
virus (HCV) by determining the serum levels of the cytokines involved in the induction of the Th17
response (TGF-b and IL-6), the cytokines produced by Th17 cells (IL-17A, IL-17F and IL-22) and the cyto-
kines whose production is stimulated by Th17 lymphocytes (IL-8 and GM-CSF). We investigated the rela-
tionships among the levels of these cytokines by assessing clinical ﬁndings, liver histology and viremia.
Sixty untreated patients and 28 healthy individuals were included in the study. Cytokine levels were
determined using ELISA. Differences between HCV and control groups were identiﬁed in the median lev-
els of IL-17F (controls = 172.4 pg/mL; HCV = 96.8 pg/mL, p < 0.001) and IL-8 (controls = 30.1 pg/mL;
HCV = 18.1 pg/mL, p < 0.05). IL-6 levels were higher in patients presenting moderate liver necroinﬂam-
mation than in patients with mild or no liver necroinﬂammation (p < 0.05). IL-17F levels were increased
in patients that had increased ALT levels. Additionally, a strong positive correlation was observed
between IL-17F and IL-22 levels in the two groups investigated, and the IL-17F/IL-22 ratio was lower
in the patients infected with HCV (p < 0.0001). Patients with low HCV viral loads had higher median levels
of IL-8 (32.5 pg/mL) than did patients with high HCV loads (16.7 pg/mL, p < 0.05). These results suggest
that in chronic hepatitis C infection, IL-17F and IL-8 could be associated with the control of liver injury
and infection, respectively.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Immunology studies involving chronic hepatitis C infection
have been performedmainly to elucidate the immunopathogenesis
and the mechanisms involved in HCV evasion of the host immune
response. Although important progress has been made in these
areas, the participation of Th17 cells in HCV chronic infection has
not been well characterized and has been documented in only a
few recent studies [1–3]. Th17 cells are a subpopulation of TCD4+
cells that produce cytokines that have been described as important
mediators of either autoimmunity or immune defense against bac-
teria, parasites and fungi, thus justifying more studies to elucidate
their involvement in HCV infection. Patients chronically infected
with hepatitis C virus can present extra-hepatic manifestation of
autoimmunity as autoantibody production. However, this immune
event has not been associated with the production of some TH17
cytokines that have been implicated in autoimmunity as IL-6,Análises Clínicas e Toxicoló-
ador, Bahia, Brazil. Tel.: +55
ier OA license.IL-17A, IL-17F or IL-22. On the other hand, recent studies have
reported that cytokines as IL-17F and IL-22 could exert biological
effects on hepatocellular carcinoma [4–6]. Therefore, this study
investigated the serum cytokine proﬁles, focusing on the most
important cytokines involved in Th17 immune responses, in pa-
tients with chronic hepatitis C. Furthermore, the association of
serum cytokine levels with clinical and laboratory ﬁndings of auto-
immunity, liver pathology and HCV viremia were investigated in
these individuals.
2. Patients, materials and methods
2.1. Patients
In this study, we included 60 untreated patients with chronic
hepatitis C: 28 men and 32 women, with a mean age of
47.8 ± 11.6 years (range = 25–69 years). All patients were from a
hepatitis reference center in Salvador, BA, Brazil. The patients
had clinical diagnosis of hepatitis C and positive serological tests
for HCV infection, including indirect ELISA, detection of HCV-RNA
by RT–PCR and HCV genotyping (Inno-LiPA HCV LineProbe Assay;
Innogenetics, Zwijndrecht, Belgium). Co-infection with HBV, HIV
Table 1
Serum levels of cytokines in healthy controls and hepatitis C patients.
Cytokine (pg/mL) Controls HCV p Value
IL-6 3.0 (2.8–4.8) 3.0 (2.2–4.4) >0.05
TGF-b 801 (673.5–801.0) 779.4 (688.7–868.1) >0.05
IL-17A 3.1 (2.3–4.8) 3.2 (2.8–3.9) >0.05
IL-17F 172.4 (114.6–232.3) 96.8 (69.8–188.1) <0.001
IL-22 10.7 (8.8–12.8) 11.1 (9.3–17.6) >0.05
IL-8 30.1 (17.2–77.2) 18.1 (11.9–36.2) <0.05
GM-CSF 15.7 (11.3–22.8) 12.3 (10.5–17.3) >0.05
Cytokine levels were determined by capture ELISA and are presented as median and
interquartile range (Q1–Q3). The medians of the groups were compared by the
Mann–Whitney test.
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used as exclusion criteria. Blood HCV loads were determined using
the AMPLICOR HCV Detection Kit v2.0 (Roche Molecular Systems
Inc., Somerville, NJ, USA). The control group consisted of 28 healthy
blood donors. Informed consent was obtained from all patients be-
fore participating in the study, which was approved by a local Eth-
ical Committee.
2.2. Liver histology
Patient liver biopsies were histologically examined using hema-
toxylin–eosin, Picrosirius red and Perls’ iron stains. The METAVIR
score [7] was used to classify liver ﬁbrosis and liver necroinﬂam-
matory activity. Liver biopsy was performed 30–90 days before
the determination of serum levels of ALT, ferritin, haptoglobin,
autoantibodies and cytokines.
2.3. Clinical chemistry
Serum alanine aminotransferase levels were determined using
an automated test (reference value <41 U/L). Haptoglobin levels
(reference value 35–195 mg/dL) were measured by nephelometry
using the IMMAGE system (Beckman-Coulter, USA), and ferritin
levels (reference values 34–155 ng/mL for men and 36–262 ng/
mL for women) were determined by capture immunoassay using
the Access 2 system (Beckman-Coulter, USA).
2.4. Autoantibodies
Anti-smooth muscle and anti-LKM-1 antibodies were tested by
IFAT using combined stomach/liver/kidney tissues (VIRO-IMMUN
Labor-Diagnostika GmbH, Oberursel, Germany). Anti-phospholipid
antibodies (anti-cardiolipin and anti-b2 glycoprotein) were de-
tected by indirect ELISA (ORGENTEC Diagnostika GmbH, Mainz,
Germany). IgM anti-IgG rheumatoid factor was assessed by neph-
elometry using the IMMAGE system (Beckman-Coulter, USA).
2.5. Cytokine immunoassays
The serum levels of IL-6, IL-17F, IL-22, GM-CSF and TGF-b were
determined using Ready-Set-Go! ELISA kits (eBioscience Inc., San
Diego, CA, USA). IL-8 and IL-17A levels were measured with ELISA
kits from Bender MedSystems (Bender MedSystems, Vienna, Aus-
tria). Their analytical sensitivities were as follows: IL-6 (1.6 pg/
mL), IL-8 (8.0 pg/mL), IL-17A (1.6 pg/mL), IL-17F (32.0 pg/mL), IL-
22 (8.0 pg/mL), GM-CSF (8.0 pg/mL) and TGF-b (8.0 pg/mL).
2.6. Statistical analysis
The distribution of the continuous variable was determined
using the D’Agostino–Pearson test. Control and HCV groups were
compared using the Mann–Whitney U test, whereas three groups
were compared with the Kruskal–Wallis test with Dunn’s Multiple
Comparison test. Proportion analysis was performed using Fisher’s
exact test, and the correlation between two categorical groups was
analyzed using the Spearman test. Statistical signiﬁcance was set
at p < 0.05. Prism version 5.1 software was used to perform the sta-
tistical analyses (GraphPad Software Inc., La Jolla, CA, USA).
3. Results
3.1. Clinical chemistry
The median ALT level in the HCV patients was 53.1 U/L
(IQR = 39.0–87.0 U/L), and a moderate increase in this enzymewas observed in 45 out of 60 (75%) patients. The median haptoglo-
bin level was 65.0 mg/dL (IQR = 44.0–105.0 mg/dL). The median
ferritin level was 149.7 ng/mL (IQR = 81.8–276.0 ng/mL). Eighteen
patients (30.0%), 9 men and 9 women, had increased levels of
ferritin.
3.2. Liver histology
The liver ﬁbrosis score varied from F0 to F2 in 50 out of 60
(83.3%) patients, whereas advanced F3–F4 ﬁbrosis was present in
10 out of 60 (16.7%) patients. Thirty-nine (67.2%) patients pre-
sented with necroinﬂammatory activity with scores of A0 or A1,
while moderate necroinﬂammatory activity was observed in 19
(32.8%) subjects.
3.3. Serum cytokine levels
The serum levels of IL-17F, IL-22 and TGF-b were determined in
all patients and controls; however, the levels of IL-6, IL-17A, GM-
CSF and IL-8 in some patients and control subjects were below
the limits of detection of the immunoassays. Thus, IL-6 levels were
determined in 23 out of 60 (38.3%) patients and in 10 out of 28
(35.7%) control subjects. IL-17A levels were determined in 39 out
of 60 (65%) patients and in 10 out of 28 (35.7%) control subjects.
GM-CSF levels were determined in 50 out of 60 (83.3%) patients
and in 26 out of 28 (92.8%) control subjects. IL-8 levels were mea-
sured in 59 out of 60 (98.3%) patients and 28 out of 28 control sub-
jects (100%).
HCV patients displayed lower levels of IL-8 and IL-17F than did
healthy controls (Table 1, p < 0.05). Positive correlations between
IL-17F and IL-22 levels were observed in both the control group
and the HCV group (r = 0.75, p < 0.0001 and r = 0.46, p < 0.001,
respectively); however, the IL-17F/IL-22 ratio was higher in the
control subjects than in the patients (Fig. 1, p < 0.0001).
Moderate positive correlations were observed between ALT lev-
els and IL-17F or TGF-b levels (r = 0.291 and r = 0.289, respectively;
p < 0.05). IL-17F levels were higher in patients with increased ALT
than in patients with normal levels of this enzyme (Fig. 2). IL-6 and
IL-22 levels did not correlate with the levels of haptoglobin or fer-
ritin (p < 0.05).
3.4. Cytokine levels and liver histology
IL-6 levels were different when the groups represented by
healthy controls, patients without liver necroinﬂammatory activity
or with mild liver necroinﬂammatory activity (A0/A1) and patients
with moderate liver necroinﬂammatory activity (A2) were com-
pared (Fig. 3, p < 0.05). Although no difference was observed be-
tween the IL-6 levels of the healthy group and those from A0/A1
patients (p = 0.05), a signiﬁcant difference was veriﬁed in the levels
of this cytokine when the two groups of HCV patients were
Table 2
Cytokine levels in HCV patients with low or high viral load of hepatitis C virus.
Cytokine (pg/
mL)
Low viral load
6400,000 IU/mL
High viral load
>400,000 IU/mL
p
value
IL-6 2.1 (1.8–16.2) 2.1 (2.0–19.7) >0.05
IL-17A 3.4 (2.7–4.0) 3.2 (2.8–3.9) >0.05
IL-17F 127.2 (75.5–226.9) 89.5 (68.2–168.1) >0.05
IL-22 11.8 (9.5–24.4) 10.7 (9.3–17.2) >0.05
TGF-b 787.2 (674.0–924.5) 817.6 (688.7–863.3) >0.05
GM-CSF 12.3 (9.8–16.4) 12.2 (10.5–20.6) >0.05
IL-8 32.5 (15.3–107.2) 16.7 (11.9–30.7) <0.05
Cytokine levels were determined by capture ELISA and are presented as median and
interquartile range (Q1–Q3). The medians of the groups were compared by the
Mann–Whitney test.
p < 0.05
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Fig. 2. Serum IL-17F levels in HCV patients presenting normal ALT level (<41 U/L,
N = 21) or high ALT level (>41 U/L, N = 38). Horizontal lines represent the medians.
The Mann–Whitney test was used to compare the medians of serum IL-17F levels in
these groups.
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Fig. 3. Serum IL-6 levels in healthy controls, HCV patients presenting mild or no
liver necroinﬂammation (A0/A1) and moderate liver necroinﬂammation (A2).
Horizontal lines represent the medians. The Kruskal–Wallistest and the Dunn’s
Multiple Comparison test were used to compare the groups.
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Fig. 1. IL-17F/IL-22 ratio in healthy controls and HCV patients. Horizontal lines
represent the medians. The Mann–Whitney test was used to compare the medians
of IL-17F/IL-22 ratios in these groups.
140 G.M. Sousa et al. / Cytokine 60 (2012) 138–142compared (A0/A1 vs. A2). In contrast, no differences in serum cyto-
kine levels were observed between patients with F0, F1 or F2 ﬁbro-
sis scores and those with advanced ﬁbrosis (F3 or F4).
3.5. Cytokine levels and autoimmunity
The presence of rheumatoid factor was observed in 33 out of 60
(55.0%) HCV patients (median level = 29 IU/mL, IQR = 23–113.5 IU/
mL). Anti-smooth muscle antibodies were detected in 12 out of 60
(20.0%) patients, and anti-phospholipid antibodies were found in
six out of 60 patients (10.0%); however, no differences in cytokine
levels were detected in the patients that were seronegative or sero-
positive for these autoantibodies (p > 0.05).
3.6. Viral loads and cytokine levels
HCV genotype 1 infection was identiﬁed in 43 out of 60 (71.7%)
patients. Twelve out of 60 subjects (20.0%) were infected with HCV
genotype 3, and ﬁve out of 60 (8.3%) were infected with HCV geno-
type 2. Similar levels of cytokines were observed when patients in-
fected with HCV genotype 1 were compared to those infected with
HCV genotypes 2 or 3 (p > 0.05). Blood HCV loads were determinedin 48 out of 60 patients (80.0%): viral loads were low (6400,000 IU/
mL) in 16 out of 48 (33.3%) patients and high (>400,000 IU/mL) in
23 out of 48 (47.9%) patients using in this classiﬁcation a pre-treat-
ment viral load cut-off previously reported [8] and adopted in our
hepatitis service. The comparison of these two groups of individu-
als showed that patients with high viral loads had lower IL-8 levels
than did patients with low HCV loads (Table 2).4. Discussion
In this study, we investigated the involvement of the Th17 im-
mune response in HCV chronic infection by determining serum
levels of the cytokines that induce Th17 responses (IL-6 and TGF-
b), the cytokines produced by Th17 cells (IL-17A, IL-17F and IL-
22) and the cytokines induced by Th17 lymphocytes (IL-8 and
GM-CSF).
The levels of ALT, ferritin, haptoglobin, autoantibodies and cyto-
kines in this study were determined using the same serum sample,
which was obtained from patients during their admission in the
study. The short time lapse of 30–90 days between liver biopsy
and cytokine level determination was important to validate the re-
sults involving liver histology and the serum levels of these im-
mune mediators in the patients with hepatitis C. In addition,
these individuals did not have co-infections and were free of im-
mune suppression, events that could provoke ﬂuctuation in both
HCV load and cytokine levels.
The HCV patients in this study did not display elevated levels of
TGF-b and IL-6. In contrast, an Indian study reported increased
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with cirrhosis and hepatocellular carcinoma were reported to have
elevated levels of TGF-b, which returned to normal levels after
treatment [9]. TGF-b has immunosuppressive activity and partici-
pates in liver ﬁbrosis by activating the transition of liver stellar
cells to myoﬁbroblast-like cells, stimulating the synthesis of extra-
cellular matrix proteins and inhibiting their degradation. The levels
of this cytokine can vary in chronic hepatitis C infection and have
been associated with its clinical evolution, as changes in TGF-b are
associated with progressive ﬁbrosis [10,11]. In our study, TGF-b
levels were moderately correlated with ALT levels, suggesting an
association with liver injury; however, most of the patients had
ﬁbrosis scores ranging from F0 to F2, explaining the normal levels
of this cytokine observed in the HCV group.
In accordance with a previous report [12], IL-6 levels were sim-
ilar in HCV patients and control subjects. Increased IL-6 levels have
been reported in chronic HCV patients with either non-Hodgkin’s B
cell lymphomas or mixed cryoglobulinemia with active vasculitis
[13,12]. Our ﬁnding that IL-6 levels were unaltered in HCV patients
may thus be explained by the lack of these clinical manifestations
in our study population; however, the levels of this cytokine were
increased in patients with moderate liver necroinﬂammatory
activity. In addition to its participation in the liver acute phase re-
sponse, IL-6 protects hepatocytes from liver injury through its anti-
apoptotic effects following activation of the oncogenic protein sig-
nal transducer and activator of transcription 3 (STAT3), which also
promotes hepatocellular carcinoma growth [14,15].
Although IL-17A levels and IL-22 levels were unaltered in HCV
patients, IL-17F levels were lower in these subjects and were also
moderately correlated with ALT levels. IL-17F is a weak inducer
of proinﬂammatory cytokines secreted by Th17 cells that provides
immune protection against infection by inducing the production of
CXC chemokines, G-CSF and antimicrobial peptides [16]. In our
study, IL-17F levels were strongly correlated with IL-22 levels in
both control subjects and HCV patients; additionally, a signiﬁcant
decrease in the IL-17F/IL-22 ratio was observed in the HCV pa-
tients. IL-22 is a member of the IL-10 cytokine family that is mainly
produced by Th17 and Th22+ cells. Expression of IL-22 is inhibited
by TGF-b. IL-22 has inﬂammatory properties, and its expression is
increased in chronic inﬂammatory diseases, such as rheumatoid
arthritis, inﬂammatory bowel disease and psoriasis. Moreover, IL-
22 participates in innate immune defense by inducing liver pro-
duction of acute-phase proteins, stimulating the production of
LPS-binding protein (LBP) and protecting the host from liver dam-
age by increasing the growth and survival of hepatocytes [17–21].
In this study, we detected no correlation between TGF-b and IL-22
levels. Furthermore, IL-22 levels were not correlated with the ser-
um levels of the acute-phase proteins haptoglobin and ferritin.
The detection of similar IL-22 serum levels in control subjects
and HCV patients conﬁrms the results of a previous study that
showed unaltered serum IL-22 levels in patients with viral hepati-
tis B or C despite the up-regulation of IL-22 expression in the livers
of these individuals [2].
The observation that the IL-17F/IL-22 ratio was decreased in
subjects infected with HCV merits future investigation. IL-17F
down-regulates IL-6, IL-8, and vascular endothelial growth factor
and inhibits angiogenesis and cancer growth, whereas IL-22 has
an opposite effect, stimulating the growth of hepatocellular carci-
nomas through STAT3 activation, promoting metastasis and inhib-
iting apoptosis [22,23]. Thus, the biological signiﬁcance of the IL-
17F/IL-22 ratio in hepatitis C must be elucidated to evaluate its
importance in liver oncology.
Although IL-6, IL-17A, IL-17F and IL-22 have been implicated in
the autoimmune mechanisms of chronic inﬂammatory diseases
such as rheumatoid arthritis, systemic lupus erythematosus, pri-
mary biliary cirrhosis and autoimmune hepatitis [5,24–29], thelevels of these cytokines were similar in all of the patients, regard-
less of their seropositivity for rheumatoid factor, anti-smooth mus-
cle, anti-cardiolipin or anti-b2 glycoprotein I antibodies. Therefore,
this ﬁnding provides additional evidence that the seropositivity for
non-organ-speciﬁc antibodies in chronic HCV infection is caused
by cross-reactivity between anti-HCV antibodies and human self-
antigens [30] or by the presence of natural poly-reactive autoanti-
bodies involved in innate immune defense.
Increased serum levels of GM-CSF and IL-8 have been reported
in chronic hepatitis C infection [31]; however, we did not observe
similar ﬁndings in this study. In accordance with a recent study
[32], although IL-8 levels were decreased in HCV subjects, the ser-
um levels of this cytokine were higher in patients with low HCV
loads than in those with high HCV loads. This ﬁnding suggests a
protective role for IL-8 in the control of HCV infection and may ex-
plain the unfavorable therapeutic response of chronic hepatitis C
patients with high IL-8 serum levels [33]. In summary, our results
suggest that IL-17F and IL-8 could play protective roles in chronic
hepatitis C infection, which seem to be associated with the control
of liver injury and infection, respectively.
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